Retrospective study of the clinical effect of incobotulinumtoxinA for the management of myofascial pain syndrome in refractory patients

Carolina Miguel; Alejandra Cirera

doi:10.1016/j.toxicon.2021.09.022

Retrospective study of the clinical effect of incobotulinumtoxinA for the management of myofascial pain syndrome in refractory patients

Toxicon. 2021 Nov:203:117-120. doi: 10.1016/j.toxicon.2021.09.022. Epub 2021 Oct 1.

Authors

Carolina Miguel¹, Alejandra Cirera²

Affiliations

¹ Physical Medicine and Rehabilitation Department, Hospital de La Vega Lorenzo Guirao, Vereda de Morcillo, S/n, 30530, Cieza, Murcia, Spain. Electronic address: carolmiguel81@hotmail.com.
² Physical Medicine and Rehabilitation Department, Hospital de La Vega Lorenzo Guirao, Vereda de Morcillo, S/n, 30530, Cieza, Murcia, Spain. Electronic address: cirtorsa@hotmail.com.

PMID: 34600908
DOI: 10.1016/j.toxicon.2021.09.022

Abstract

The aim was to evaluate the effectiveness and safety of IncobotulinumtoxinA (IncoA) for the management of myofascial pain syndrome (MPS) in refractory patients. This single-center, observational, retrospective study includes 37 patients. The pain reduction was 4.7 points (95%CI: 5.6 to -3.8) from baseline to one-month post-injection (using a 10-point visual analogue scale). Only 18.9% experienced mild adverse events. In conclusion, IncoA is an effective and safe alternative for the treatment of MPS in refractory patients.

Keywords: Efficacy; Myofascial pain syndrome; Safety; incobotulinumtoxinA.

Publication types

Observational Study

MeSH terms

Botulinum Toxins, Type A* / therapeutic use
Humans
Myofascial Pain Syndromes* / drug therapy
Pain Measurement
Retrospective Studies
Treatment Outcome

Substances

Botulinum Toxins, Type A
incobotulinumtoxinA